Alnylam hops on AI train with up to $2B Inceptive partnership
BioSpace
Alnylam Pharmaceuticals will leverage Inceptive Nucleics' generative machine learning models to accelerate the development of RNA interference therapies.
pharminent
June 4, 2026 (Last updated: June 4, 2026)
BioSpace
Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.
